222 related articles for article (PubMed ID: 35772170)
21. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
Casonato A; Pontara E; Sartorello F; Bertomoro A; Durante C; Girolami A
J Lab Clin Med; 2001 Jan; 137(1):70-6. PubMed ID: 11150026
[TBL] [Abstract][Full Text] [Related]
22. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
23. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
[TBL] [Abstract][Full Text] [Related]
24. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
25. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
27. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease.
Baronciani L; Federici AB; Cozzi G; Canciani MT; Mannucci PM
J Thromb Haemost; 2007 Feb; 5(2):282-8. PubMed ID: 17155947
[TBL] [Abstract][Full Text] [Related]
28. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
[TBL] [Abstract][Full Text] [Related]
29. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
[TBL] [Abstract][Full Text] [Related]
30. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B "Malmö/New York" von Willebrand disease.
Lavenu-Bombled C; Guitton C; Dupuis A; Baas MJ; Desconclois C; Dreyfus M; Li R; Caron C; Gachet C; Fressinaud E; Lanza F
Thromb Haemost; 2016 Nov; 116(6):1070-1078. PubMed ID: 27683759
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
32. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
33. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
34. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
35. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
[TBL] [Abstract][Full Text] [Related]
37. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?
Casonato A; Pontara E; Bertomoro A; Sartorello F; Cattini MG; Girolami A
Br J Haematol; 2001 Mar; 112(3):578-83. PubMed ID: 11260057
[TBL] [Abstract][Full Text] [Related]
38. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.
Casonato A; Gallinaro L; Cattini MG; Pontara E; Padrini R; Bertomoro A; Daidone V; Pagnan A
Haematologica; 2010 Aug; 95(8):1366-72. PubMed ID: 20305138
[TBL] [Abstract][Full Text] [Related]
39. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease.
Ragni MV; Jankowitz RC; Chapman HL; Merricks EP; Kloos MT; Dillow AM; Nichols TC
Haemophilia; 2008 Sep; 14(5):968-77. PubMed ID: 18680527
[TBL] [Abstract][Full Text] [Related]
40. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.
Larsen DM; Haberichter SL; Gill JC; Shapiro AD; Flood VH
Haemophilia; 2013 Jul; 19(4):590-4. PubMed ID: 23496210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]